The Experts below are selected from a list of 42885 Experts worldwide ranked by ideXlab platform
Frederic Liote - One of the best experts on this subject based on the ideXlab platform.
-
efficacy of anakinra for refractory acute calcium pyrophosphate crystal Arthritis
2012Co-Authors: Anna Molto, Pascal Richette, Thomas Bardin, Frederic LioteAbstract:Abstract Acute synovitis induced by deposition of calcium pyrophosphate (CPP) and monosodium urate crystals involves interleukin-1β production and activation. The efficacy of blocking interleukin-1β activity (with an interleukin-1 receptor antagonist [anakinra] or interleukin-1β antibody) is well documented for gout attacks but has only been reported in two single-case reports of CPP Crystal-Induced acute Arthritis. Here we report on five cases (four males, mean age 71 ± 27) of CPP Crystal-Induced inflammatory Arthritis refractory and/or intolerant to usual drug therapy and efficiently treated with anakinra. Diagnosis of CPP Crystal-Induced Arthritis was confirmed by identification of crystals in synovial fluid. CPP Crystal-Induced oligo-Arthritis (n = 4) and polyArthritis (n = 1) were refractory to conventional treatments, including non-steroidal anti-inflammatory drugs, colchicine and steroids (systemic administration or intra-articular injection). After latent infection was ruled out, anakinra, 100 mg/day, was administered subcutaneously for 3 days. Four patients showed rapid clinical and biological responses at a mean of 3 days after treatment. Anakinra provided good joint pain relief (baseline 0–100 mm visual analog scale score 60 ± 17 mm, outcome 10 ± 10 mm) and decreased serum C-reactive protein level (58 ± 43 to 5 ± 2 mg/L). Anakinra was well tolerated. One injection-site skin reaction was observed but no infection. Anakinra was effective and safe in this small series of patients with refractory Arthritis due to acute CPP crystal deposition.
Daniel Wendling - One of the best experts on this subject based on the ideXlab platform.
-
efficacy of anakinra in calcium pyrophosphate crystal induced Arthritis a report of 16 cases and review of the literature
2013Co-Authors: Sebastien Ottaviani, Lauren Brunier, Jean Sibilia, F Maurier, Marc Ardizzone, Daniel Wendling, Ghislaine Gill, Elisabeth Palazzo, Olivier Meyer, Philippe DieudeAbstract:Abstract Objectives Calcium pyrophosphate (CPP) Crystal-Induced Arthritis occurs particularly in elderly people. This population has frequently associated comorbidities and treatments, which could limit the use of conventional therapies (colchicine, non-steroidal anti-inflammatory drugs and corticosteroids). The aim of the study was to evaluate the efficacy and tolerance of anakinra in patients with CPP Crystal-Induced Arthritis. Methods We performed a multicentric retrospective chart review of patients who received anakinra for CPP Crystal-Induced Arthritis. Demographic information, comorbidities, co-prescription, short-term treatment outcomes, adverse event, complication and subsequent flares were reviewed. Results A total of 16 patients (12 females, mean age: 80.2 ± 11.1 years) received anakinra (100 mg subcutaneously per day). The mean number of anakinra injection was 15.5 ± 42.9 per patient (median: 3). All patients had contraindication and/or failure to conventional therapies. The majority (14 [87.5%]) of patients with CPP Crystal-Induced Arthritis demonstrated a beneficial response to anakinra therapy: 10 good responses and four partial responses. A relapse occurred in six (37.5%) patients (mean time to relapse: 3.4 ± 4.9 months). One patient had an acute bacterial pneumonitis. Conclusion Our results suggest that anakinra is relatively well tolerated and could be a good option in the treatment of CPP Crystal-Induced Arthritis, illustrating that IL-1β blockade may be helpful to control flares in patients having CPP Crystal-Induced Arthritis for which conventional therapies are ineffective or contra-indicated.
-
il1 blockade in crystal induced Arthritis impact of disease duration and the inflammatory syndrome comments on the article by couderc m et al efficacy of anakinra in articular chondrocalcinosis
2013Co-Authors: Frank Verhoeven, Clement Prati, Marie Godfrinvalnet, Xavier Guillot, Daniel WendlingAbstract:Joint Bone Spine - In Press.Proof corrected by the author Available online since jeudi 25 octobre 2012
Philippe Dieude - One of the best experts on this subject based on the ideXlab platform.
-
efficacy of anakinra in calcium pyrophosphate crystal induced Arthritis a report of 16 cases and review of the literature
2013Co-Authors: Sebastien Ottaviani, Lauren Brunier, Jean Sibilia, F Maurier, Marc Ardizzone, Daniel Wendling, Ghislaine Gill, Elisabeth Palazzo, Olivier Meyer, Philippe DieudeAbstract:Abstract Objectives Calcium pyrophosphate (CPP) Crystal-Induced Arthritis occurs particularly in elderly people. This population has frequently associated comorbidities and treatments, which could limit the use of conventional therapies (colchicine, non-steroidal anti-inflammatory drugs and corticosteroids). The aim of the study was to evaluate the efficacy and tolerance of anakinra in patients with CPP Crystal-Induced Arthritis. Methods We performed a multicentric retrospective chart review of patients who received anakinra for CPP Crystal-Induced Arthritis. Demographic information, comorbidities, co-prescription, short-term treatment outcomes, adverse event, complication and subsequent flares were reviewed. Results A total of 16 patients (12 females, mean age: 80.2 ± 11.1 years) received anakinra (100 mg subcutaneously per day). The mean number of anakinra injection was 15.5 ± 42.9 per patient (median: 3). All patients had contraindication and/or failure to conventional therapies. The majority (14 [87.5%]) of patients with CPP Crystal-Induced Arthritis demonstrated a beneficial response to anakinra therapy: 10 good responses and four partial responses. A relapse occurred in six (37.5%) patients (mean time to relapse: 3.4 ± 4.9 months). One patient had an acute bacterial pneumonitis. Conclusion Our results suggest that anakinra is relatively well tolerated and could be a good option in the treatment of CPP Crystal-Induced Arthritis, illustrating that IL-1β blockade may be helpful to control flares in patients having CPP Crystal-Induced Arthritis for which conventional therapies are ineffective or contra-indicated.
Thomas Bardin - One of the best experts on this subject based on the ideXlab platform.
-
efficacy of anakinra for refractory acute calcium pyrophosphate crystal Arthritis
2012Co-Authors: Anna Molto, Pascal Richette, Thomas Bardin, Frederic LioteAbstract:Abstract Acute synovitis induced by deposition of calcium pyrophosphate (CPP) and monosodium urate crystals involves interleukin-1β production and activation. The efficacy of blocking interleukin-1β activity (with an interleukin-1 receptor antagonist [anakinra] or interleukin-1β antibody) is well documented for gout attacks but has only been reported in two single-case reports of CPP Crystal-Induced acute Arthritis. Here we report on five cases (four males, mean age 71 ± 27) of CPP Crystal-Induced inflammatory Arthritis refractory and/or intolerant to usual drug therapy and efficiently treated with anakinra. Diagnosis of CPP Crystal-Induced Arthritis was confirmed by identification of crystals in synovial fluid. CPP Crystal-Induced oligo-Arthritis (n = 4) and polyArthritis (n = 1) were refractory to conventional treatments, including non-steroidal anti-inflammatory drugs, colchicine and steroids (systemic administration or intra-articular injection). After latent infection was ruled out, anakinra, 100 mg/day, was administered subcutaneously for 3 days. Four patients showed rapid clinical and biological responses at a mean of 3 days after treatment. Anakinra provided good joint pain relief (baseline 0–100 mm visual analog scale score 60 ± 17 mm, outcome 10 ± 10 mm) and decreased serum C-reactive protein level (58 ± 43 to 5 ± 2 mg/L). Anakinra was well tolerated. One injection-site skin reaction was observed but no infection. Anakinra was effective and safe in this small series of patients with refractory Arthritis due to acute CPP crystal deposition.
Pascal Richette - One of the best experts on this subject based on the ideXlab platform.
-
efficacy of anakinra for refractory acute calcium pyrophosphate crystal Arthritis
2012Co-Authors: Anna Molto, Pascal Richette, Thomas Bardin, Frederic LioteAbstract:Abstract Acute synovitis induced by deposition of calcium pyrophosphate (CPP) and monosodium urate crystals involves interleukin-1β production and activation. The efficacy of blocking interleukin-1β activity (with an interleukin-1 receptor antagonist [anakinra] or interleukin-1β antibody) is well documented for gout attacks but has only been reported in two single-case reports of CPP Crystal-Induced acute Arthritis. Here we report on five cases (four males, mean age 71 ± 27) of CPP Crystal-Induced inflammatory Arthritis refractory and/or intolerant to usual drug therapy and efficiently treated with anakinra. Diagnosis of CPP Crystal-Induced Arthritis was confirmed by identification of crystals in synovial fluid. CPP Crystal-Induced oligo-Arthritis (n = 4) and polyArthritis (n = 1) were refractory to conventional treatments, including non-steroidal anti-inflammatory drugs, colchicine and steroids (systemic administration or intra-articular injection). After latent infection was ruled out, anakinra, 100 mg/day, was administered subcutaneously for 3 days. Four patients showed rapid clinical and biological responses at a mean of 3 days after treatment. Anakinra provided good joint pain relief (baseline 0–100 mm visual analog scale score 60 ± 17 mm, outcome 10 ± 10 mm) and decreased serum C-reactive protein level (58 ± 43 to 5 ± 2 mg/L). Anakinra was well tolerated. One injection-site skin reaction was observed but no infection. Anakinra was effective and safe in this small series of patients with refractory Arthritis due to acute CPP crystal deposition.